- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 208
Rapt adapts IPO stance
The Celgene and GV-backed cancer and atopic dermatitis drug developer is now targeting $75m in an initial public offering it postponed in August.
Oct 24, 2019Mastercard sends for SessionM in acquisition deal
Salesforce Ventures is set to exit customer engagement platform developer SessionM, which has agreed to a purchase by Mastercard.
Oct 24, 2019SoftBank sorts We Company with $9.5bn financing package
Jin Jiang International and Legend Holdings will get exit routes through the deal, which is set to give SoftBank a stake in the workspace provider sized at about 80%.
Oct 23, 2019PropertyGuru moves away from IPO
Emtek, which had planned to sell as much as $55m worth of shares, will have to wait longer for an exit after the real estate marketplace withdrew from the proposed offering.
Oct 23, 2019Roku attacks $150m Dataxu acquisition
Sky will exit through the deal without much of a return, having reportedly invested in video ad buying platform Dataxu at a $1bn valuation.
Oct 23, 2019MediaLab rescues Kik Messenger
MediaLab has bought Kik Messenger from Tencent-backed Kik Interactive, saving the app from closure amid the latter's legal issues surrounding its crypto token.
Oct 22, 2019Xandr commissions Duke-backed Clypd
AT&T advertising unit Xandr has bought Clypd, a TV advertising optimisation service that counts Duke University as a shareholder.
Oct 21, 2019Clypd attaches itself to AT&T
Tivo and RTL exited television advertising data platform Clypd in an acquisition by AT&T's advertising services subsidiary, Xandr.
Oct 21, 2019TV Time clocks up MediaMorph acquisition
Liberty Global Ventures and Motorola Mobility Ventures both scored exits from the media content monetisation service in an acquisition by TV Time.
Oct 21, 2019Phathom measures out IPO terms
Takeda is set to emerge with almost 26% of Phathom Pharmaceuticals, which has licensed one of its gastrointestinal disease drugs, and which is targeting $158m.
Oct 17, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


